Lilly registers 192-person Phase 3 trial of orforglipron in Chinese adults with obesity

Eli Lilly has registered a 192-participant Phase 3 trial of orforglipron in Chinese adults with obesity or overweight who also have weight-related health problems ^[1]. The registry listing is marked not yet recruiting, and no start date, dosing plan or completion date has been disclosed ^[1].

Orforglipron is the oral GLP-1 pill Lilly sells in the United States as Foundayo ^[2]. The company has been pushing the drug into new markets since its U.S. approval, and regulatory reviews for the pill were ongoing in more than 40 markets as of August ^[2]. Lilly has said it also plans a regulatory submission for Foundayo's use in type 2 diabetes this year ^[2].

The new study is small by Phase 3 standards and is limited to participants in China ^[1]. It does not replace or duplicate the larger Lilly trials already running; it adds a country-specific dataset to a program that is being reviewed across dozens of regulators ^[1][2].

The oral market it is entering

The oral GLP-1 category is already contested. Novo Nordisk holds the lead with its Wegovy pill, which accounted for about 90% of weekly oral GLP-1 prescriptions as of July, according to analyst figures cited by BioSpace — roughly 1.5 million people, many of them new to the drug class ^[2]. Novo has separately started a Phase 3 study testing two lower maintenance doses of oral Wegovy ^[2].

The wider obesity market is the reason both companies keep expanding. Obesity therapeutics reached $66 billion in sales last year and could grow to between $105 billion and $200 billion by 2027 and beyond, according to IQVIA ^[2].

Why it matters for patients

A trial run only in China does not by itself change what is available, covered or priced in the United States. U.S. availability depends on the Food and Drug Administration's review of the drug, not on where a company runs an additional Phase 3 study, and it has not been reported whether results from this Chinese trial would be included in U.S. or other regulatory filings ^[1][2].

What the registration does show is that Lilly is still investing in orforglipron's evidence base rather than treating the pill's approval as the end of the work. For patients weighing an oral option against an injectable, more late-stage testing generally means more information about how the drug performs in different populations — though it also means more results that have not yet been published. No enrollment, dosing or outcome data from this study exist yet ^[1].

Cost and access remain separate questions. In the U.S., the temporary Medicare GLP-1 Bridge program that began in July is estimated to expand coverage of obesity medications by about 35% and give roughly 20 million potential patients access through the program, according to analyst estimates cited by BioSpace ^[2]. That program applies to the U.S., not to China, and nothing in the new trial registration addresses pricing in either country ^[1][2].

What happens next

Lilly has several near-term milestones beyond this study. A regulatory submission for Foundayo in type 2 diabetes is planned for this year, and a submission for the next-generation obesity drug retatrutide is planned for early 2027 ^[2]. Lilly could also report mid-stage results this year for the antibody bimagrumab and the oral small molecule naperiglipron, both aimed at obesity ^[2].

On the Novo side, late-stage trials of the oral obesity drug zenagamtide and high-dose cagrilintide are expected to begin by the end of the year, and a regulatory decision on CagriSema is expected in the fourth quarter ^[2]. Roche is expected to report Phase 2 data for enicepatide, with a study completion date of Sept. 24 and a company Pharma Day on Sept. 28 ^[2]. AstraZeneca is expected to present data on the amylin drug AZD6234 at the European Association for the Study of Diabetes meeting from Sept. 28 to Oct. 2 in Italy ^[2].

For the Chinese orforglipron trial itself, no enrollment start, completion date or results timeline has been reported ^[1].